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ABSTRACT
Aspirin decreases the risk of recurrent thrombotic events in patients with coronary artery disease or peripheral 
artery disease but the risk of recurrent events remains high. Long ‑term dual antiplatelet therapy 
or the combination of aspirin and warfarin further reduces the risk of recurrent events, but at the cost 
of increased bleeding, and neither of these treatments reduce mortality. The COMPASS (Cardiovascular 
Outcomes in People Using Anticoagulation Strategies) randomized controlled trial involving 27 395 patients 
from 602 sites in 33 countries (Poland: 9 sites, 518 patients) tested whether low ‑dose anticoagulant therapy 
with the coagulation factor Xa inhibitor rivaroxaban given alone or combined with aspirin reduced thrombotic 
risk compared with aspirin in patients with apparently stable chronic coronary and/or peripheral artery 
disease. In patients treated with the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg 
once daily, compared with aspirin alone, the primary outcome of the composite of cardiovascular death, 
stroke, or myocardial infarction was decreased by 24% (hazard ratio, 0.76; 95% confidence interval, 0.66 to 0.86; 
P <0.001), and mortality by 18% at the cost of a 70% increase in major bleeding but no significant increase 
in fatal or intracranial bleeding. Results were consistent in patients with coronary artery disease or peripheral 
artery disease, and the greatest absolute benefit was evident in the highest risk patients, including those 
with polyvascular disease, mild or moderate heart failure, chronic kidney disease, or diabetes. These results 
establish the combination of low ‑dose rivaroxaban and aspirin as a highly effective treatment to decrease 
morbidity and mortality rates in patients with atherosclerotic vascular disease.
further reduced nonfatal CV events, but none 
have significantly reduced mortality.5,6 Further‑
more, even with antiplatelet drug combinations, 
patients with a history of myocardial infarction 
(MI) have substantial residual thrombotic risk.5
Rivaroxaban is a direct oral anticoagulant 
that targets coagulation factor Xa. In the ATLAS 
ACS‑2 TIMI 51 (Anti ‑Xa Therapy to Lower Car‑
diovascular Events in Addition to Standard Ther‑
apy in Subjects with Acute Coronary Syndrome‑
‑Thrombolysis in Myocardial Infarction 51) tri‑
al, low ‑dose rivaroxaban (2.5 mg twice daily) 
compared with placebo on a background of sin‑
gle or dual antiplatelet therapy decreased MACE 
Introduction Cardiovascular (CV) disease 
affects more than 300 million people and 
is the leading cause of death worldwide.1 Life 
expectancy at birth in Poland was 77.5 years 
in 2015, which is more than 3 years shorter than 
the European Union average. The higher mortali‑
ty rates in Poland appear to be explained primar‑
ily by CV mortality, which remains high despite 
a reduction in CV disease mortality over the past 
10 years.2,3 Aspirin is widely used for long ‑term 
secondary prevention of CV disease because it re‑
duces major adverse CV events (MACEs) by 19% 
and mortality by 10%.4 Several antithrombotic 
regimens tested as alternatives to aspirin have 
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and mortality with an acceptable bleeding pro‑
file.7 The mean duration of treatment in the AT‑
LAS ACS‑2 TIMI 51 trial was 13.1 months with 
a maximum follow up of 31 months.
Building on the findings of the ATLAS ACS‑2 
TIMI 51 study, the COMPASS (Cardiovascu‑
lar Outcomes in People Using Anticoagulation 
Strategies) trial tested the hypothesis that long‑
‑term treatment with rivaroxaban, given alone 
or in combination with aspirin, would be su‑
perior to aspirin for the prevention of MACE, 
major adverse limb events (MALEs), and mor‑
tality in patients with apparently stable chron‑
ic coronary artery disease (CAD) or peripher‑
al artery disease (PAD). In a second partial fac‑
torial design, the COMPASS trial also tested 
whether pantoprazole, a proton pump inhibitor, 
compared with placebo reduced upper gastro‑
intestinal bleeding in patients with stable CAD 
or PAD who were not already treated with a pro‑
ton pump inhibitor.8 The main results of COM‑
PASS demonstrated that the combination of ri‑
varoxaban and aspirin, compared with aspirin 
alone, reduced the risk of both MACE and mor‑
tality, whereas rivaroxaban alone was not supe‑
rior to aspirin. Pantoprazole compared with pla‑
cebo did not reduce upper gastrointestinal tract 
complications, defined as the composite of overt 
bleeding, upper gastrointestinal bleeding from 
a gastroduodenal lesion or of unknown origin, 
occult bleeding, symptomatic gastroduodenal 
ulcer or 5 or more erosions, upper gastrointes‑
tinal obstruction, or perforation.9
In this paper, we consider the potential impact 
of the combination of rivaroxaban and aspirin 
on the burden of CV disease in Poland. The spe‑
cific objectives of this paper are: to 1) review 
the burden of CV disease in Poland; 2) summa‑
rize the new evidence from the COMPASS trial 
concerning the efficacy and safety of the combi‑
nation of rivaroxaban and aspirin for long ‑term 
prevention of MACE in patients with chronic 
CAD or PAD; and 3) provide practical informa‑
tion on managing patients with CAD or PAD 
in Poland in light of these results.
Burden of cardiovascular disease in Po-
land CV disease was the cause of an estimat‑
ed 384 500 years lived with disability and 182 000 
deaths in Poland in 2016.10,11 The introduction 
of a national public health program in Poland 
in the 1990s, and a corresponding increase in 
the number of cardiology units and angioplas‑
ty procedures was associated with a decrease in 
CV disease mortality from 52% of all deaths in 
1990, to 46% of all deaths in 2000, and 44% of all 
deaths in 2010.12 At the same time, the average 
life expectancy in Poland has increased from 75.2 
years for women and 66.2 years for men in 1990, 
to 81.8 years for women and 74.0 years for men 
in 2017.13 Despite these advances, CV disease re‑
mains a major cause of morbidity and mortality 
TABLE 1 Cardiovascular ‑disease related mortality and morbidity rates in European 
countries3 (continued on the next page)
Country Mortality Estimated DALY
Latest year Women Men Women Men
Albania 2004 724.5 950.7 98 102
Armenia 2012 743.9 946.5 NR NR
Austria 2014 348.0 457.1 58 63
Azerbaijan 2007 944.7 1078.1 65 85
Belarus 2011 726.9 1448.0 136 194
Belgium 2012 252.9 357.1 46 56
Bosnia and Herzegovina 2011 805.2 918.6 92 109
Bulgaria 2012 959.6 1299.5 149 187
Croatia 2013 581.2 761.4 87 102
Cyprus 2012 343.9 428.8 31 42
Czech Republic 2013 538.2 747.6 76 94
Denmark 2012 229.9 337.6 37 49
Estonia 2012 572.4 920.3 95 126
Finland 2013 295.6 480.7 51 76
France 2011 174.1 275.2 36 44
Georgia 2014 608.7 891.6 130 159
Germany 2013 362.1 477.2 62 72
Greece 2012 391.3 485.0 69 85
Hungary 2013 646.3 921.3 102 128
Iceland 2009 297.5 441.6 28 35
Ireland 2012 290.2 420.5 29 40
Israel 2013 194.9 255.0 23 28
Italy 2012 290.0 393.8 51 57
Kazakhstan 2012 437.5 779.9 103 146
Kyrgyzstan 2013 1087.4 1443.9 64 89
Latvia 2012 718.6 1156.8 134 177
Lithuania 2012 706.4 1096.9 105 137
Luxembourg 2013 254.9 332.7 36 41
Malta 2014 317.0 407.7 44 58
Montenegro 2009 829.4 922.3 110 114
The Netherlands 2013 233.5 332.0 38 46
Norway 2013 235.1 334.7 38 46
Poland 2013 505.6 756.0 74 106
Portugal 2013 259.7 347.0 43 52
Republic of Moldova 2013 1071.6 1380.2 131 155
Romania 2012 903.9 1143.9 111 139
Russian Federation 2011 914.0 1423.1 150 217
San Marino 2005 322.0 516.6 NR NR
Serbia 2013 836.4 990.9 111 125
Slovakia 2010 758.5 1048.1 81 107
Slovenia 2010 390.6 532.9 53 58
R E V I E W  A R T I C L E   Benefits of COMPASS trial results in Polish patients 663
TABLE 1 Cardiovascular ‑disease related mortality and morbidity rates in European 
countries3 (continued from the previous page)
Country Mortality Estimated DALY
Latest year Women Men Women Men
Spain 2013 221.5 292.4 39 48
Sweden 2013 292.3 414.8 50 60
Switzerland 2013 242.0 339.2 37 44
Tajikistan 2004 920.0 1332.5 57 52
FYR Macedonia 2010 1012.5 1228.8 NR NR
Turkey 2013 458.2 582.7 53 72
Turkmenistan 1998 1300.0 1748.3 104 150
Ukraine 2012 1065.8 1544.9 177 214
United Kingdom 2013 227.9 334.3 39 53
Uzbekistan 2005 1225.1 1492.4 74 89
Mortality is expressed as age ‑standardized mortality rate. Estimated DALY per 1000 population data 
is from 2012.
Abbreviations: DALY, disability adjusted life years; FYR, the former Yugoslav Republic of; NR, not 
reported
in Poland and is the leading cause of the number 
of years of life lost.14,15 Compared with the coun‑
try with the highest life expectancy in Europe in 
2017, life expectancy for women in Poland was 
4.7 years lower (ranked twenty ‑fifth) and for men 
was 7.8 years lower (ranked twenty ‑eight).13 Re‑
duced life expectancy in Poland has numerous 
possible mechanisms, including a high preva‑
lence of CV disease risk factors and lack of suf‑
ficient focus on early detection of atheroscle‑
rotic disease including PAD. Thus, patients with 
CV disease in Poland could benefit from a new 
strategy to reduce the risk of MACE, MALE, and 
mortality. The burden of CV disease in Poland 
is shown and compared with other European 
countries in TABLE 1.
Design of the COMPASS trial COMPASS was 
a multicenter, double ‑blind, double ‑dummy, su‑
periority trial that included patients with a his‑
tory of apparently stable chronic atherosclerotic 
vascular disease.16 Patients were eligible if they 
had a history of CAD and/or PAD. The defini‑
tions of CAD and PAD, as well as inclusion and 
exclusion criteria, are shown in TABLE 2. Eligible 
patients were randomized to the combination 
of rivaroxaban 2.5 mg twice daily and aspirin 
100 mg once daily, rivaroxaban 5 mg twice dai‑
ly (and placebo aspirin), or aspirin 100 mg once 
daily (and placebo rivaroxaban).
The rivaroxaban doses of 2.5 mg and 5 mg 
twice daily were chosen based on the results 
of the ATLAS ACS 2‑TIMI 51 trial, in which ri‑
varoxaban 2.5 mg twice daily, compared with 
placebo, on a background of standard antiplate‑
let therapy, reduced MACE (9.1% versus 10.7%; 
hazard ratio [HR], 0.84; 95% confidence interval 
[CI], 0.72–0.97), increased thrombolysis in myo‑
cardial infarction major bleeding (1.8% vs 0.6%; 
HR, 3.46; 95% CI, 2.08–5.77) and reduced mor‑
tality (2.9% vs 4.5%; HR, 0.68; 95% CI, 0.53–
0.87) in patients with recent acute coronary syn‑
drome. Rivaroxaban 5 mg twice daily also re‑
duced MACE and increased bleeding, but did 
not significantly reduce mortality.7
The  primary outcome of  COMPASS was 
the  composite of  CV death, stroke, and MI. 
The secondary outcomes were 1) ischemic stroke, 
MI, acute limb ischemia (ALI), or death from 
coronary heart disease; 2) ischemic stroke, 
MI, ALI, or CV death; 3) death from any cause. 
MALE was defined as ALI (limb ‑threatening 
ischemia which is confirmed by limb hemody‑
namics or imaging and leads to acute vascu‑
lar intervention, peripheral artery surgery / re‑
construction, or peripheral angioplasty / stent 
or amputation) or chronic limb ischemia (con‑
tinuing ischemic limb, foot, or digit pain lead‑
ing to hospitalization and intervention and not 
meeting the definition of ALI, or Fontaine stage 
III or IV at baseline with peripheral intervention 
during the course of the trial). The main safety 
TABLE 2  Definitions of eligibility criteria from the COMPASS trial8 (continued on 
the next page)
CAD is defined as
Myocardial infarction within the last 20 years, or
Multi vessel coronary diseasea with symptoms or with history of stable or unstable 
angina, or
Multi vessel percutaneous coronary intervention, or
Multi vessel coronary artery bypass graft surgery
PAD is defined as
Previous aortofemoral bypass surgery, limb bypass surgery, or percutaneous 
transluminal angioplasty revascularization of the iliac, or infra ‑inguinal arteries, or
Previous limb or foot amputation for arterial vascular disease, or
History of intermittent claudication and ≥1 of the following:
– An ankle/arm blood pressure ratio <0.90, or
– Significant peripheral artery stenosis (≥50%) documented by angiography, 
or duplex ultrasound, or
– Previous carotid revascularization or asymptomatic carotid artery stenosis ≥50% as 
diagnosed by duplex ultrasound or angiography
Inclusion criteria
Willing and able to provide written informed consent
Criteria for CAD and PAD met
Patients with CAD must also meet at least 1 of the following criteria:
– Age ≥65, or
– Age <65 and documented atherosclerosis or revascularization involving at least 2 
vascular bedsb or at least 2 additional risk factors
– Current smoker (within 1 year of randomization)
– Diabetes mellitus
– Renal dysfunction with estimated glomerular filtration rate <60 ml/min
– Heart failure
– Nonlacunar ischemic stroke ≥1 month ago
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a history of hypertension, 38%, a history of di‑
abetes, 3.8%, a prior stroke, and 62%, a previ‑
ous MI. A high proportion of patients enrolled 
in the trial were receiving other proven second‑
ary prevention therapies. Lipid ‑lowering agents 
were used in 90% of patients, angiotensin con‑
verting enzyme (ACE) inhibitor or angiotensin 
receptor blocker in 71%, β ‑blockers in 70%, and 
diuretics in 29%. The patients included in COM‑
PASS are comparable to those enrolled in prior 
trials testing alternatives to aspirin for long‑
‑term prevention of CV events.
Results of the COMPASS trial The combi‑
nation of rivaroxaban and aspirin, compared 
with aspirin, reduced the primary outcome 
by 24% (absolute risk, 4.1% vs 5.4%; HR, 0.76; 
95% CI, 0.66–0.86; P <0.001) and mortality 
by 18% (absolute risk, 3.4% vs 4.1%; HR, 0.82; 
95% CI, 0.71–0.96; P = 0.01), as shown in TABLE 3. 
Each of the components of the primary out‑
come was reduced, including CV death by 22% 
(absolute risk, 1.7% vs 2.2%; HR, 0.78; 95% CI, 
0.64–0.96; P = 0.02), stroke by 42% (absolute 
risk, 0.9% vs 1.6%; HR, 0.58; 95% CI, 0.44–0.76; 
P <0.001), and MI by 14% (absolute risk, 1.9% 
vs 2.2%; HR, 0.86; 95% CI, 0.70–1.05; P = 0.14). 
The combination also reduced MALE (HR, 0.54; 
95% CI, 0.35–0.84; P = 0.0054). These bene‑
fits were achieved at the cost of an increase in 
major bleeding (absolute risk, 3.1% vs 1.9%; 
HR, 1.70; 95% CI, 1.40–2.05; P <0.001) and 
primarily gastrointestinal bleeding (absolute 
risk, 1.5% vs 0.7%; HR, 2.15; 95% CI, 1.60–2.89; 
P <0.001). There was no significant increase in 
fatal or critical organ bleeding, and the com‑
bination produced a significant net clinical 
benefit (absolute risk, 4.7% vs 5.9%; HR, 0.80; 
95% CI, 0.70–0.91; P <0.001).8,18,19 There was no 
significant benefit of rivaroxaban alone com‑
pared with aspirin.
The effect of the combination of rivaroxaban 
and aspirin compared with aspirin on the pri‑
mary outcome was consistent in subgroups de‑
fined by age, sex, geographic region, body weight, 
renal function, and history of CV risk factors. 
The benefits of rivaroxaban and aspirin were ev‑
ident in patients who were already treated with 
lipid lowering, blood pressure lowering, and ACE 
inhibitor therapy, and in those at low, interme‑
diate, and high risk of subsequent CV events. 
The magnitude of the benefit from rivaroxaban 
and aspirin appears to be at least comparable 
to the benefit from other proven secondary pre‑
vention therapies such as lipid lowering, blood 
pressure lowering, and ACE inhibitor therapy, 
as shown in TABLE 4.
Results in the subgroups with coronary or pe-
ripheral artery disease The majority of pa‑
tients enrolled in COMPASS had CAD (24 824 
patients [91%]) and 69% of these patients had 
outcome was based on a modification of the In‑
ternational Society on Thrombosis and Haemo‑
stasis definition of major bleeding, and included 
fatal bleeding, symptomatic bleeding into a crit‑
ical organ, bleeding into a surgical site requiring 
reoperation, and bleeding that led to hospital‑
ization.16,17 The net clinical benefit outcome was 
a composite of the primary outcome, fatal bleed‑
ing, or symptomatic bleeding into a critical organ.
A total of 27 395 patients from 602 centers in 
33 countries, including 518 patients from 9 sites 
in Poland, were randomized to one of the 3 in‑
tervention arms in a 1:1:1 ratio. Prior to random‑
ization, potentially eligible patients had to suc‑
cessfully complete a 30‑day run ‑in phase during 
which they were adherent to aspirin and rivar‑
oxaban placebo at least 80% of the time.
At baseline, the median age of participants 
was 68.2 years, 22% were women, 75% had 
TABLE 2  Definitions eligibility criteria from the COMPASS trial8 (continued from 
the previous page)
Exclusion criteria
High risk of bleeding
Stroke within 1 month or any history of hemorrhagic or lacunar stroke
Severe heart failure with known ejection fraction <30% or NYHA class 
III or IV symptoms
Estimated glomerular filtration rate <15 ml/min
Need for dual antiplatelet therapy, other nonaspirin antiplatelet therapy, or oral 
anticoagulant therapy
Known noncardiovascular disease that is associated with poor prognosis (eg, 
metastatic cancer) or that increases the risk of an adverse reaction to study 
interventions
History of hypersensitivity or known contraindication for rivaroxaban, aspirin, 
pantoprazole, or excipients, if applicable
Systemic treatment with strong inhibitors of both cytochrome P450 CYP3A4 isozyme 
and p ‑glycoprotein (eg, systemic azole antimycotics, such as ketoconazole, and HIV‑
‑protease inhibitors, such as ritonavir), or strong inducers of CYP3A4, ie, rifampicin, 
rifabutin, phenobarbital, phenytoin, and carbamazepine
Any known hepatic disease associated with coagulopathy
Patients who are pregnant, breastfeeding, or are of childbearing potential, and 
sexually active and not practicing an effective method of birth control (eg, surgically 
sterile, prescription oral contraceptives, contraceptive injections, intrauterine 
device, double ‑barrier method, contraceptive patch, male partner sterilization)
Previous assignment to treatment during this study
Concomitant participation in another study with investigational drug
Known contraindication to any study related procedures
An additional exclusion for the pantoprazole randomization is the need for continuous 
treatment with a proton pump inhibitor
a Refers to stenosis of ≥50% in 2 or more coronary arteries, confirmed by invasive coronary 
angiography, or noninvasive imaging or stress studies (eg, exercise or pharmacologic) suggestive 
of significant ischemia in 2 or more coronary territories; or in 1 coronary territory if at least 1 other 
territory has been revascularized
b Because CAD involves disease in the coronary vasculature, only one additional vascular bed 
is required; eg, the aorta, arterial supply to the brain, gastro ‑intestinal tract, lower limbs, upper 
limbs, kidneys
Abbreviations: CAD, coronary artery disease; PAD, peripheral artery disease; NYHA, New York Heart 
Association
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TABLE 3  COMPASS trial results8,18,19
Study group Rivaroxaban + 
aspirin, n (%)
Aspirin, n (%) Rivaroxaban + aspirin versus aspirin
HR (95% CI) P value
Overall groupa
Efficacy, 
primary 
outcome
CV death, stroke, or MI 379 (4.1) 496 (5.4) 0.76 (0.66–0.86) <0.001
Ischemic stroke, MI, ALI, or death from CHD 329 (3.6) 450 (4.9) 0.72 (0.63–0.83) <0.001
Ischemic stroke, MI, ALI, or CV death 389 (4.3) 516 (5.7) 0.74 (0.65–0.85) <0.001
Death from any cause 313 (3.4) 378 (4.1) 0.82 (0.71–0.96) 0.01
Safety Major bleeding 288 (3.1) 170 (1.9) 1.70 (1.40–2.05) <0.001
Fatal bleeding 15 (0.2) 10 (0.1) 1.49 (0.67–3.33) 0.32
Nonfatal symptomatic ICH 21 (0.2) 19 (0.2) 1.10 (0.59–2.04) 0.77
Nonfatal, non ‑ICH, symptomatic bleeding 
to critical organ
42 (0.5) 29 (0.3) 1.43 (0.89–2.29) 0.14
Minor bleeding 838 (9.2) 503 (5.5) 1.70 (1.52–1.90) <0.001
NCB CV death, stroke, MI, fatal bleeding, 
or symptomatic bleeding into critical organ
431 (4.7) 534 (5.9) 0.80 (0.70–0.91) <0.001
CAD groupb
Efficacy Primary outcome: MI, stroke or CV death 347 (4.2) 460 (5.6) 0.74 (0.65–0.86) <0.0001
MI, ischemic stroke, CHD death, or ALI 299 (3.6) 411 (5.0) 0.72 (0.62–0.83) <0.0001
MI, ischemic stroke, CV death, or ALI 349 (4.2) 470 (5.7) 0.73 (0.64–0.84) <0.0001
Death 262 (3.2) 339 (4.1) 0.77 (0.65–0.90) 0.0012
Safety Major bleeding 263 (3.2) 158 (1.9) 1.66 (1.37–2.03) <0.0001
Fatal bleeding 14 (0.2) 9 (0.1) 1.55 (0.67–3.58) 0.30
Nonfatal symptomatic ICH 19 (0.2) 19 (0.2) 0.99 (0.52–1.87) 0.98
Nonfatal, non ‑ICH, symptomatic bleeding 
into critical organ
36 (0.4) 25 (0.3) 1.42 (0.85–2.36) 0.18
NCB CV death, stroke, MI, fatal bleeding 
or symptomatic bleeding into a critical organ
392 (4.7) 494 (6.0) 0.78 (0.69–0.90) 0.0003
PAD groupc
Efficacy Primary outcome: CV death, stroke, MI 126 (5.0) 174 (6.9) 0.72 (0.57–0.90) 0.0047
CHD death, MI, ischemic stroke, ALI 115 (4.6) 169 (6.7) 0.68 (0.53–0.86) 0.0011
CV death, MI, ischemic stroke, ALI 142 (5.7) 198 (7.9) 0.71 (0.57–0.88) 0.0019
Death 129 (5.2) 142 (5.7) 0.91 (0.72–1.16) –
Safety Major bleeding 77 (3.1) 48 (1.9) 1.61 (1.12–2.31) 0.0089
Fatal bleeding 4 (0.2) 3 (0.1) – –
Nonfatal symptomatic ICH 4 (0.2) 8 (0.3) – –
Nonfatal, non ‑ICH symptomatic bleeding 
into critical organ
13 (0.5) 8 (0.3) 1.55 (0.64–3.74) 0.33
NCB CV death, MI, stroke, and critical organ 
or fatal bleeding
140 (5.6) 185 (7.4) 0.75 (0.60–0.94) 0.011
CV death, MI, stroke or MALE, major 
amputation, or fatal or critical organ bleeding
169 (6.8) 234 (9.3) 0.72 (0.59–0.87) 0.0008
a Total number of patients, 27 394; patients on rivaroxaban plus aspirin, 9152; patients on aspirin, 9126;  b Total number of patients, 24 824; patients on rivaroxaban 
plus aspirin, 8313; patients on aspirin, 8261;  c Total number of patients, 7470; patients on rivaroxaban plus aspirin, 2492; patients on aspirin, 2504
Abbreviations: ALI, acute limb ischemia; CHD, coronary heart disease; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; ICH, intracranial hemorrhage; MALE, 
major adverse limb event; MI, myocardial infarction; NCB, net clinical benefit; others, see TABLE 2
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Polyvascular disease was defined as patients 
with vascular disease involving more than 1 
vascular bed (CAD, PAD, or cerebrovascular 
disease). The subgroup with polyvascular dis‑
ease mostly consisted of patients with both 
CAD and PAD (n = 4906), with a smaller num‑
ber having both cerebrovascular disease and 
CAD or both cerebrovascular disease and PAD. 
Patients with polyvascular disease, compared 
with those without polyvascular disease, had 
a higher risk of MACE when treated with aspi‑
rin alone (8.5% for 2 major vascular beds and 
7.9% for 3 major vascular beds, vs 4.6% for pa‑
tients without polyvascular disease). Treat‑
ment with rivaroxaban and aspirin, compared 
with aspirin alone, produced a consistent rela‑
tive risk reduction in MACE, and the absolute 
risk reduction (ARR) in MACE was higher in 
patients with polyvascular disease (2.7% for 2 
major vascular beds and 3.3% for 3 major vas‑
cular beds) than in patients without polyvas‑
cular disease (0.8%).
Patients with diabetes mellitus, compared 
with those without a history of diabetes melli‑
tus, had a high risk of MACE when treated with 
aspirin alone (6.9% vs 4.6%). Treatment with 
rivaroxaban and aspirin produced a consistent 
relative risk reduction in MACE, and the ARR 
in MACE was higher in patients with diabetes 
mellitus (1.7%) than in those without diabetes 
mellitus (1.0%).
HF was defined as the presence of at least 
1 sign (dependent edema, increased jugular ve‑
nous pressure, rales) or 1 symptom (shortness 
of breath, orthopnea, paroxysmal nocturnal 
dyspnea), plus either 1 positive diagnostic test 
(B‑type natriuretic peptide >500 pg/ml, or N 
terminal pro ‑B‑type natriuretic peptide >2000 
pg/ml, or chest x ‑ray showing pulmonary con‑
gestion, edema, or pleural effusion) or need‑
ing diuretic, nitrate, or inotropic agent to treat 
the HF. Patients with HF were analyzed because 
a history of MI. In patients with CAD, treat‑
ment with rivaroxaban and aspirin reduced 
the risk of the primary outcome by 26%, stroke 
by 44% and mortality by 23%. Major bleeding 
increased by 66%, but fatal bleeding, nonfatal 
symptomatic intracranial hemorrhage, or bleed‑
ing into a critical organ were not significant‑
ly increased.19 Consistent benefits of rivarox‑
aban and aspirin treatment were evident irre‑
spective of whether patients were enrolled less 
than 2 years, 2 to 5 years, or more than 5 years 
after previous MI and in those without a his‑
tory of MI.
A post hoc analysis suggested that the addi‑
tional risk of bleeding in the rivaroxaban and 
aspirin group, compared with aspirin, decreased 
over time, whereas the reduction in the prima‑
ry outcome was constant.
PAD was present in 7470 patients, of whom 
3402 (46%) had intermittent claudication and 
ankle ‑brachial index (ABI) of more than 0.90, 
2045 (27%) had previous revascularization 
surgery, 4129 (55%) had symptomatic PAD 
of the lower extremities, and 1919 (26%) had 
carotid artery disease. Treatment with rivarox‑
aban and aspirin, compared with aspirin alone, 
reduced the primary outcome by 28%, increased 
major bleeding by 61%, and decreased the pre‑
specified limb outcomes of ALI by 44%, MALE by 
46%, all vascular amputations by 60%, major am‑
putation by 70%, and MALE plus major amputa‑
tion by 46%. The reduction in MACE and MALE 
was consistent in the subgroups with symptom‑
atic PAD, PAD of the lower extremities, and ca‑
rotid artery disease.
Highest-risk patients The greatest absolute 
benefit of rivaroxaban and aspirin was seen 
in patients who were at highest risk of MACE, 
such as patients with polyvascular disease, and 
those with diabetes mellitus, heart failure (HF), 
or chronic kidney disease (CKD).
TABLE 4  Magnitude of the benefits of rivaroxaban and aspirin compared with other proven and widely accepted secondary treatments for 
cardiovascular prevention
Proven secondary prevention treatments Rivaroxaban + aspirin on top of proven 
secondary prevention treatments
Lipid lowering
by 1 mmol/l20,21
BP lowering
by 10 mm Hg22
ACE inhibitors23,24 β ‑Blockers25 Rivaroxaban 2.5 mg bid
+ aspirin8
MACE 21% 20% 18% – 24%
Mortality 9% 13% 14% 20% 18%
Stroke 15% 27% 23% – 42%
MI 24% 17% 18%b 25% 14%a
Data are presented as relative risk reduction.
a Not statistically significant;  b Nonfatal myocardial infarction
Abbreviations: ACE, angiotensin‑converting enzyme; bid, twice daily; BP, blood pressure; MACE, major adverse cardiovascular event; others, see TABLE 3
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with rivaroxaban and aspirin treatment com‑
pared with aspirin treatment.28
How do the results of the COMPASS trial 
add to prior knowledge? The results from 
the COMPASS trial show, for the first time, 
that long term antithrombotic therapy with 
the combination of an antiplatelet and an an‑
ticoagulant in patients with CAD and PAD pro‑
duces significant reductions in both morbid‑
ity and mortality rates. These benefits were 
achieved in apparently stable patients already 
well treated with proven secondary prevention 
therapies. Previous trials with combinations 
of aspirin and clopidogrel, ticagrelor, vorapaxar, 
or warfarin reduced nonfatal CV events at the 
cost of increased bleeding but did not reduce 
mortality. The results of COMPASS redefine 
the concept of residual thrombotic risk, widen‑
ing it from a mainly lipid mediated definition 
to vascular/thrombotic risk and provide a sig‑
nificant tool for further reductions of mortal‑
ity in stable CAD.29
Approval of rivaroxaban 2.5 mg tablets by 
regulatory authorities In 2018, the Commit‑
tee for Medicinal Products for Human Use from 
the European Medicines Agency, United States 
Food and Drug Administration, and Health Can‑
ada approved the combination of rivaroxaban 
and aspirin for treatment of patients with sta‑
ble CAD or PAD.30 -32 The European Medicines 
Agency decision is automatically valid and bind‑
ing for the territories of each European Union 
member state, including Poland.
Practical implications of COMPASS for coun-
tries with high cardiovascular disease bur-
den In countries like Poland, where the CV 
disease morbidity and mortality are very high, 
the benefits of rivaroxaban 2.5 mg twice dai‑
ly and aspirin treatment for patients and po‑
tential cost ‑effectiveness when taking into 
account the lifelong risk is likely to be partic‑
ularly pronounced.2 9 While the specific phar‑
macoeconomic analysis for Poland is awaited, 
the results in high risk patients suggest that 
the COMPASS treatment strategy may be par‑
ticularly effective in Poland for patients with 
stable CAD or PAD. Patients with chronic vas‑
cular disease who derive the greatest benefit 
from the combination of rivaroxaban and as‑
pirin treatment are those with polyvascular 
disease, mild to moderate HF, CKD, or dia‑
betes mellitus. Such patients had the highest 
event rates in COMPASS and therefore gain 
the greatest absolute benefit from the combi‑
nation of rivaroxaban and aspirin treatment.
A key target population for the COMPASS 
treatment regimen should include patients with 
concomitant CAD and PAD who are at partic‑
ularly high risk. Patients with polyvascular 
a subgroup analysis of the ATLAS ACS‑2 TIMI 
51 trial showed that the benefits of rivaroxa‑
ban for reduction of MACE were greater in pa‑
tients with HF than in those without HF.26 Mild 
or moderate heart failure was present in ap‑
proximately 5902 (21.5%) COMPASS patients. 
Patients with HF had a higher risk of MACE 
than patients without HF when treated with 
aspirin alone (7.9% vs 4.7%). In this subgroup, 
treatment with rivaroxaban and aspirin, com‑
pared with aspirin alone, produced a consistent 
relative risk reduction in MACE, and the ARR 
in MACE was larger in patients with HF (2.4%) 
than in patients without HF (1.0%). The net clin‑
ical benefit of rivaroxaban and aspirin therapy, 
compared with aspirin, was an ARR of 2.4% in 
patients with HF, which equates to a number 
needed to treat of 42.2 7
Patients with CKD (defined as stage 3 CKD 
or higher, estimated glomerular filtration rate 
<60 ml/min), compared with those without CKD, 
had a higher risk of MACE when treated with as‑
pirin alone (8.4% vs 4.6%). Treatment with ri‑
varoxaban and aspirin, compared with aspirin 
alone, produced a consistent relative risk reduc‑
tion in MACE, and the ARR in MACE was larger 
in patients with CKD (1.9%) than in those with‑
out CKD (1.1%).
The larger ARR in MACE with the combina‑
tion of rivaroxaban and aspirin, compared with 
aspirin alone, was evident in patients with poly‑
vascular disease, diabetes mellitus, HF, or CKD 
because these subgroups have a higher base‑
line risk of MACE than patients without these 
features.
Graft failure after coronary artery bypass 
graft Aspirin reduces the risk of graft failure 
and MACE in patients who have had a coronary 
artery bypass graft (CABG), but is only modestly 
effective. Hypothesizing that the addition of ri‑
varoxaban to aspirin reduces the risk of graft 
failure and MACE, 1448 patients who had CABG 
surgery within the previous 4 to 14 days were 
randomized to the COMPASS trial and had 
CABG graft patency evaluated with a comput‑
ed tomography angiogram 1 year after surgery. 
Triple vessel CAD was present in 77.8% of pa‑
tients, double vessel disease in 17.1%, and more 
than 70% of patients underwent on ‑pump sur‑
gery. There was no significant risk reduction in 
the risk of graft occlusion with aspirin and rivar‑
oxaban (9.1% vs 8.0%; odds ratio [OR], 1.13; 95% 
CI, 0.82 to 1.57; P = 0.45) or rivaroxaban (7.8% 
vs 8.0%; OR, 0.95; 95% CI, 0.67 to 1.33; P = 0.75), 
compared with aspirin. However, the risk re‑
duction of  MACE with rivaroxaban and as‑
pirin compared to aspirin (2.4% vs 3.5%; HR, 
0.69; 95% CI, 0.33 to 1.47; P = 0.34) was consis‑
tent with the risk reduction seen in non ‑CABG 
patients. Fatal bleeding or tamponade with‑
in 30 days of randomization was not increased 
KARDIOLOGIA POLSKA  2019; 77 (7-8)668
disease have almost a doubled risk of MACE 
when compared to patients with disease in a sin‑
gle vascular bed and achieve the greatest ARR 
in MACE with combination therapy.3 3 While 
a second vascular bed can include carotid ath‑
erosclerosis, the results in patients with PAD 
of the lower extremity are particularly relevant. 
PAD is highly prevalent in Poland with 30 000 
to 40 000 new diagnoses of PAD every year ac‑
cording to Polish National Health Fund data.3 4 
The prevalence of PAD is 3% to 10% in the gen‑
eral population and up to 20% in patients above 
65 years of age, whereas asymptomatic PAD is 3‑ 
to 4‑fold more common. While PAD can be rel‑
atively easily diagnosed (for example by means 
of ABI), this is not routinely performed in pa‑
tients with atherosclerosis. The results of the 
COMPASS trial support the noninvasive eval‑
uation of atherosclerosis in other vascular beds, 
especially PAD of the lower limbs. The lack of ef‑
fective preventive measures and therapeutic 
approaches in a pre ‑COMPASS era has been 
identified as a primary cause of low popular‑
ity of ABI testing in patients with CAD. Late 
diagnosis of PAD is also associated with limit‑
ed access to vascular medicine specialists and 
vascular surgeons in Poland. Many patients 
reach these reference centers when severe isch‑
emic symptoms have already developed, leading 
to a high rate of amputation (ranging between 
9000–11 000/y) and MALE in PAD patients in 
Poland. In the light of these facts, the introduc‑
tion of combination of rivaroxaban 2.5 mg twice 
daily with aspirin provides an extremely valu‑
able therapeutic option that can be introduced 
by general physicians and internists.
In whom should the COMPASS treatment 
be avoided? Rivaroxaban and aspirin treat‑
ment should be avoided in patients who cannot 
tolerate or have a contraindication to aspirin 
or rivaroxaban, have an unacceptable bleeding 
risk, or who require long ‑term dual antiplate‑
let therapy. Bleeding in patients who take an‑
tithrombotic therapy is associated with an in‑
creased risk of subsequent CV events.35
Aspirin dose in COMPASS regimen An is‑
sue raised in the discussions of COMPASS tri‑
al is that aspirin 100 mg once daily was used 
in combination with rivaroxaban 2.5 mg twice 
daily. In Poland the typical dose of aspirin used 
is 75 mg once daily. Considering the pharmaco‑
kinetics of aspirin and the results of previous 
randomized trials evaluating different doses 
of aspirin, a 75‑mg dose of aspirin can be used 
instead of 100 mg.36
Rivaroxaban: management of bleeding Ex‑
perience in the COMPASS trial indicates that 
bleeding that occurs in patients treated with 
the combination of rivaroxaban 2.5 mg twice 
daily and aspirin can be readily managed. Most 
of the excess bleeds were gastrointestinal, with 
no significant increase in fatal bleeding, intra‑
cranial bleeding, or symptomatic bleeding into 
a critical organ. Most gastrointestinal bleeds 
can be managed by interrupting rivaroxaban 
and aspirin and supportive measures until he‑
mostasis is achieved. Gastrointestinal or gen‑
itourinary bleeding that develops in patients 
who are treated with rivaroxaban and aspi‑
rin should prompt investigations for under‑
ling cancer that may have been unmasked by 
the treatment.
Rivaroxaban: perioperative interruption The 
time for offset of the anticoagulant effects of ri‑
varoxaban 2.5 mg twice daily is likely short‑
er than for rivaroxaban 20 mg once daily (be‑
cause at lower doses rivaroxaban have a shorter 
half ‑life) and peak drug levels are much lower. 
For patients who take rivaroxaban 20 mg dai‑
ly and have creatinine clearance of 30 ml/min 
or higher, the last dose of rivaroxaban should 
be taken no less than 48 hours prior to surgery 
which has a low bleeding risk, or no less than 
72 hours prior surgery which has a high bleed‑
ing risk. For patients with creatinine clearance 
15 to 29.9 ml/min, the last dose of rivaroxa‑
ban should be taken no less than 72 hours prior 
to surgery which has a low bleeding risk, or no 
less than 96 hours prior to surgery which has 
a high bleeding risk.37 A similar approach is rea‑
sonable for patients treated with the combina‑
tion of rivaroxaban 2.5 mg twice daily and aspi‑
rin, although it may be overly conservative, as 
taking the last dose of rivaroxaban 24 hours pri‑
or to most types of surgery is likely to provide 
enough time for the effect of low doses of rivar‑
oxaban to offset, which was tested in COMPASS.
Conclusion The COMPASS trial supports 
the efficacy of low dose rivaroxaban and aspirin 
for secondary prevention in patients with sable 
CAD or PAD. The reduction in MACE, with con‑
sistent reductions in the individual components 
of CV death, stroke, and MI, as well as reduc‑
tions in MALE and overall mortality have not 
been previously demonstrated with long ‑term 
antithrombotic therapies. Despite an increase 
in major bleeding with rivaroxaban and aspirin 
treatment, there is no significant increase in fa‑
tal or intracranial bleeding and the net clinical 
benefit is in favor of rivaroxaban and aspirin 
treatment. The benefit of rivaroxaban and as‑
pirin treatment appears to be of at least similar 
magnitude to other proven secondary preven‑
tion therapies. The patients with CAD or PAD 
who will benefit most from this new strategy are 
those with polyvascular disease, mild or moder‑
ate HF, diabetes, or CKD. Clinicians in Poland 
now have rivaroxaban 2.5 mg tablets available 
to use in combination with aspirin. This new 
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